A 45-year-old Indian national has been sentenced to 43 months in prison for conspiring to sell tens of thousands of dollars’ worth of counterfeit cancer medication that he privately compared to “just ...

An Indian national has been sentenced for conspiring to sell counterfeit cancer drugs in the US, highlighting the dangers of ...

A Houston federal judge has sent a counterfeit cancer drug seller to prison for nearly four years after investigators discovered vials labeled as Keytruda that contained no real cancer-fighting ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s. King Keytruda, Merck’s blockbuster PD-1 inhibitor, has kept ...

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...

Merck (MRK) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's ...

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...

The combination of Padcev and Keytruda has once again delivered strong results, this time significantly improving overall survival (OS) for patients with cisplatin-eligible muscle-invasive bladder ...

Event-free survival improved with EV/pembro: median not reached vs 48.5 months, and 24‑month EFS 79.4% vs 66.2% with cisplatin/gemcitabine. Overall survival separated early (24‑month 86.9% vs 81.3%), ...

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...